Bio-Rad Labs (NYSE: BIO) reported Q4 EPS of $3.10, $0.28 better than the analyst estimate of $2.82. Revenue for the quarter came in at $681.18 million versus the consensus estimate of $685 million.

OUTLOOK

Full-Year 2024 Financial Outlook

Bio-Rad is providing its financial outlook for the full year 2024. The company currently expects non-GAAP, currency-neutral revenue growth of approximately 1.0 to 2.5 percent and an estimated non-GAAP operating margin of approximately 13.5 to 14.0 percent.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.